Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12427510 | 0.88 | GNAO1 (0.50) | L3MBTL1EPHX1EPHX2CARM1PRMT6 | |
| SCHEMBL27317530 | 0.83 | CARM1 (0.64) | L3MBTL1CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12605183 | 0.83 | L3MBTL1 (0.47) | L3MBTL1EPHX1EPHX2CARM1PRMT6 | |
| SCHEMBL22544374 | 0.82 | L3MBTL1 (0.51) | L3MBTL1EPHX1EPHX2CARM1PRMT6 | |
| SCHEMBL26042777 | 0.80 | CARM1 (0.50) | L3MBTL1EPHX1EPHX2CARM1PRMT6 | |
| SCHEMBL14488004 | 0.79 | L3MBTL1 (0.49) | L3MBTL1CARM1PRMT6GNAO1GNAI3 | |
| SCHEMBL22544376 | 0.79 | L3MBTL1 (0.49) | L3MBTL1EPHX1EPHX2CARM1PRMT6 | |
| SCHEMBL23806826 | 0.79 | EPHX1 (0.43) | L3MBTL1EPHX1EPHX2CARM1PRMT6 | |
| SCHEMBL18636713 | 0.79 | L3MBTL1 (0.49) | L3MBTL1CARM1PRMT6GNAO1GNAI3 | |
| SCHEMBL25144481 | 0.78 | GBA1 (0.37) | L3MBTL1CARM1PRMT6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885EPHX1 1684/4885EPHX2 1890/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885EPHX1 1684/4885EPHX2 1890/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885EPHX1 1684/4885EPHX2 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.